Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 32, 2000 - Issue 2
Submit an article Journal homepage
6
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Subcutaneous Interleukin-2 in Combination with Anti-retroviral Therapy for Treatment of HIV-1-Infected Subjects

Carsten S. Larsen, Lars Østergård, Bjarne K. MØller, Mads R. Buhl Department of Medicine and Infectious Diseases, Aarhus University Hospital, Marselisborg Hospital, DK-8000 Aarhus, Denmark
Pages 153-160 | Published online: 08 Jul 2009

  • Fauci AS. The human immunodeficiency virus: infectivity and mechanism of pathogenesis. Science 1988; 239: 617–22.
  • Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 T lymphocytes in HIV infection. Nature 1995; 373: 123–6.
  • Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117–22.
  • Wolthers KC, Wisman GBA, Otto SA, de Roda Husman AM, Schaft N, de Wolf F, et al. T cell teleomere length in HIV-1 infection: no evidence for increased CD4 + cell turnover. Science 1996; 274: 1543–7.
  • Clerici M, Shearer GM. A Th1 → Th2 switch is a critical step in the etiology of HIV infection. Immunology Today 1993; 14: 107–11.
  • Lipsky JJ. Antiretroviral drugs for AIDS. The Lancet 1996; 348: 800–3.
  • Carpenter CCJ, Fischl M, Hammer S, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS society-USA panel. JAMA 1997; 277: 1962–9.
  • Gullick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–9.
  • Pantaleo G. How immune-based interventions can change HIV therapy. Nature Medicine 1997; 3: 483–6.
  • Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, et al. HIV infection induces changes in CD4 + T cell phenotype and depletions within the CD4 + T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Medicine 1997; 3: 533–40.
  • Robb RJ. Interleukin-2: the molecule and its function. Immunology Today 1984; 5: 203–9.
  • Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 234: 1169–76.
  • Lifson JD, Benike CJ, Mark DF, Koths K, Engleman EG. Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS. Lancet 1984 Mar 31; 1(8379): 698–702.
  • Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332: 567–75.
  • Kovacs JA, Vogel S, Albert JM. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 336: 1350–6.
  • Sleijfer DT, Jansen RAJ, Buter J, de Vries EGE, Willemse PHB, Mulder NH. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992; 10: 1119–23.
  • Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, et al. Biological activity of recombinant human interleukin-2 produced in Eschericia coli. Science 1984; 223: 1412–4.
  • Wang A, Lu S-D, Mark DF. Site-specifik mutagenesis of the human interleukin-2 gene: Structure-function analysis of the cysteine residues. Science 1984; 224: 1431–3.
  • McMahon DK, Armstrong JA, Huang X, Rinaldo CR, Gupta P, Whiteside TL, et al. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 1994; 8: 59–66.
  • Bernstein ZP, Porter M, Gould M, Lipman B, Bluman EM, Stewart CC, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995; 9: 3287–94.
  • Jacobson LJ, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996; 93: 10405–10.
  • Davey RT, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175: 781–9.
  • Hennge UR, Goos M, Esser S, Exner V, Dötterer H, Wiehler H, et al. Randomized, contolled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998; 12: F225–34.
  • Witzke O, Winterhagen T, Reinhardt Heemann U, GrosseWilde H, Kreuzfelder E. Roggendorf M, et al. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV-disease. J Intern Med 1998; 244: 235–240.
  • Piscitelli SC, Wells BS, Metcalf JA, Baseler M, Stevens R, Davey RT. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 HIV-infected patients. Pharmacotherapy 1996; 16: 754–9.
  • Delta Coordinating Committee. Delta: a randomized doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–91.
  • Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081–90.
  • Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, et al. Safety and efficacy of lamivudine-zi-dovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276: 118–25.
  • Bartlett JA, Berend C, Petroni GR, Ottinger J, Tyler DL, Pettinelli C, et al. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. J Infect Dis 1998; 178: 1170–3.
  • Akbar AN, Salmon M. Cellular enviroments and apoptosis: tissue microenviroments control activated T cell death. Immunol Today 1997; 18: 72–6.
  • Adachi A, Oyaizu N, Than S, McCloskey TW, Pahwa S. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. Correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 1996; 157: 4184–93.
  • Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167–70.
  • Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996; 10: 859–65.
  • Ho H-N, Hultin LE, Mitsuyasu RT, Matud JL, Hausner MA, Bockstoce D, et al. Circulating HIV-specific CD8 + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993; 150: 3070–9.
  • Carr A, Emery S, Lloyd A, Hoy J, Garsia R, French M, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J Infect Dis 1998; 178: 992–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.